1. Home
  2. SBI vs ZNTL Comparison

SBI vs ZNTL Comparison

Compare SBI & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Intermediate Muni Fund Inc

SBI

Western Asset Intermediate Muni Fund Inc

HOLD

Current Price

$7.76

Market Cap

109.7M

Sector

Finance

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$1.41

Market Cap

118.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBI
ZNTL
Founded
1992
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
109.7M
118.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SBI
ZNTL
Price
$7.76
$1.41
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$5.87
AVG Volume (30 Days)
39.5K
500.8K
Earning Date
01-01-0001
11-10-2025
Dividend Yield
4.52%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$26,865,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.96
$1.01
52 Week High
$8.00
$3.72

Technical Indicators

Market Signals
Indicator
SBI
ZNTL
Relative Strength Index (RSI) 44.40 49.05
Support Level $7.76 $1.34
Resistance Level $7.84 $1.45
Average True Range (ATR) 0.05 0.06
MACD 0.01 0.01
Stochastic Oscillator 46.67 52.94

Price Performance

Historical Comparison
SBI
ZNTL

About SBI Western Asset Intermediate Muni Fund Inc

Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager. The Fund also maintains a dollar-weighted average effective maturity of between three and ten years.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: